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Perioperative death is considered a leading cause of morbidity and mortality in the United States.1 The main cause of perioperative death includes acute organ inju-
ries, for example, myocardial infarction (MI), acute respira-
tory distress syndrome (ARDS), acute kidney injury (AKI), 
and acute gut injury (AGI). While perioperative physicians 
acknowledge the detrimental impact of perioperative organ 
injury on surgical outcomes, opportunities to intervene are 
extremely limited. For example, clinical studies indicate 
that AKI has a highly detrimental impact on surgical out-
comes, including cardiac and noncardiac surgery.2 In addi-
tion, even small increases of creatinine elevations below AKI 
definition are associated with a doubling of morbidity and 
prolonged hospital length of stay.2 In many instances, organ 
injury occurs at the interface of hypoxia and inflammation 
and is associated with the stabilization of hypoxia-inducible 
transcription factors (HIFs; Figures 1 and 2). HIFs belong to 
a group of transcription factors that mediate adaptation to 
hypoxia and are stabilized during a number of inflammatory 
conditions and diseases.4–6 Hypoxia and inflammation share 
an interdependent relationship because inflammation causes 
hypoxia and hypoxia causes inflammation.3 On 1 hand, 
many inflammatory diseases are characterized by hypoxia 
and stabilization of HIFs, as a result of alterations in tissue 
metabolism and increased oxygen demand from infiltrating 
immune cells. For instance, lung inflammation observed in 
acute lung injury (ALI) is associated with metabolic altera-
tions leading to the stabilization of HIF-1α.7 On the other 
hand, disease conditions that are primarily caused by lack 
of oxygen are characterized by inflammatory changes. For 
example, inflammatory responses are often observed in isch-
emia and reperfusion injury during solid organ transplanta-
tion and are the culprit for subsequent organ dysfunctions.5
As shown in Figure 1, hypoxia occurs during conditions of 
inflammation or infection with increased oxygen demand and 
decreased local oxygen supply leading to HIF stabilization. 
Decreased local oxygen supply can also be traced back to the 
compression of vasculature and vascular thrombosis, which 
further intensify tissue hypoxia. During inflammation, the 
infiltration of inflammatory cells, especially neutrophils, chal-
lenge the oxygen supply in the local microenvironment during 
tissue inflammation. Indeed, an elegant study by Campbell 
et al8 demonstrated the role of transmigrating neutrophils as 
oxygen scavengers in the mucosal microenvironment, leading 
to the stabilization of HIF. Besides “inflammatory hypoxia” 
and the great oxygen demand of inflammatory cells, processes 
after an acute infection can also result in the stabilization of 
HIF. Lipopolysaccharide (LPS), found in the outer membrane 
of Gram-negative bacteria, can elicit strong immune responses 
via toll-like receptor 4 signaling.9 Several studies indicated the 
ability of LPS or bacterial infection in the stabilization of HIF, 
suggesting an oxygen-independent way to activate HIF.10,11
Importantly, although hypoxia can be proinflammatory 
and lead to breakdown of mucosal and vascular barriers, 
the adaptive response to hypoxia, especially HIF stabiliza-
tion, bears anti-inflammatory and tissue-protective aspects. 
Indeed, many studies show that pharmacological stabiliza-
tion of HIF by HIF activators protects against tissue dam-
age.4 Herein, we discuss how hypoxia signaling can be 
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targeted therapeutically in patients as a potential treatment 
approach for the prevention or treatment of perioperative 
organ injury. This is particularly important due to the fact 
that many surgical procedures are performed electively and 
thereby provides the opportunity to introduce prophylactic 
treatment approaches to prevent perioperative organ inju-
ries. Furthermore, future strategies may allow identifica-
tion of patients at risk for a specific type of organ injury and 
facilitate the implementation of preventative measures.12
The oxygen-sensing pathway and detailed regulation 
of HIFs are illustrated in Figure  2. Briefly, HIFs are αβ-
heterodimeric transcription factors that are essential to 
hypoxia adaptation, orchestrating transcriptional programs 
that regulate metabolism and maintain tissue homeostasis 
during hypoxic conditions.13,14 Under normal oxygen lev-
els, HIF-1α and HIF-2α proteins are rapidly degraded in 
a process that involves hydroxylation by oxygen-sensing 
prolyl hydroxylases (PHDs) and binding of the von Hippel-
Lindau (VHL) gene product.15,16 This process promotes 
polyubiquitination and subsequent proteasomal degrada-
tion. Hypoxic conditions result in the functional inhibition 
of PHDs because PHDs require oxygen as cofactor, which 
stops the hydroxylation and in turn stabilizes HIFs.17 Upon 
stabilization, HIF-1α forms a complex with the β-subunit 
and translocates into the nucleus to mediate transcriptional 
regulation by binding to hypoxia-responsive elements of 
target genes.18,19 Interestingly, it is estimated that over 5% 
of all human genes are direct target genes of HIFs, which 
include genes that control cell metabolism, modulate 
inflammation, regulate apoptosis, and promote angiogen-
esis.20 Thus, targeting hypoxia signaling via modulation of 
HIFs may potentially have a profound impact on periop-
erative organ injury. Studying the HIF pathway for organ 
protection appears to be highly timely, as the 2016 Albert 
Figure 1. Links between hypoxia and inflamma-
tion in perioperative organ injury. Left side of 
this figure shows examples of clinical conditions 
characterized by tissue hypoxia, which causes 
inflammation, including pulmonary edema, 
acute kidney injury, and ischemia/reperfusion 
injury. Inflammatory diseases that lead to tis-
sue hypoxia are demonstrated in the right side 
of the figure, including acute lung injury, acute 
gut injury, and infection with pathogens. The 
interdependent relationship between inflamma-
tion and hypoxia renders hypoxia-inducible factor 
activation a desirable therapeutic intervention for 
perioperative organ injury. The figure is adapted 
from Eltzschig and Carmeliet.3 Copyright © 2011 
Massachusetts Medical Society.
Figure 2. Regulation of hypoxia-inducible factor 
(HIF) protein levels under normoxic or hypoxic 
conditions. Under normoxic conditions, hydroxyl-
ation at 2 proline residues by prolyl hydroxylases 
(PHDs) promotes HIF-α association with von 
Hippel-Lindau (VHL) and leads to HIF-α destruc-
tion via the ubiquitin/proteasome pathway. In 
hypoxia, these processes are suppressed, allow-
ing HIF-α subunits (both HIF-1α and HIF-2α) to 
escape proteolysis, dimerize with HIF-1β, translo-
cate to the nucleus, and activate transcription via 
hypoxia-response element (HREs). HIF activation 
by PHD inhibitors, conservative oxygenation, isch-
emic preconditioning (IPC), and remote ischemic 
preconditioning (RIPC) can be potential therapeu-
tic approaches for perioperative organ injury.
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Lasker Basic Medical Research Award has honored 3 phy-
sician-scientists for their contribution to the discovery of 
the pathway by which mammalian cells sense and adapt to 
changes in oxygen availability.
During perioperative organ injury, the accompanying 
tissue damage results in the release of various mediators, 
for example, resolvins, maresins, and protectins from mac-
rophages,21 as well as purines, particularly extracellular 
adenosine triphosphate (ATP) and adenosine diphosphate 
(ADP) from various cell types (Figure 3). This pathway is 
under the direct control of hypoxia signaling, as the enzy-
matic production of extracellular adenosine and some of the 
adenosine receptors are HIF-target genes. Specifically, extra-
cellular adenosine is generated by the breakdown of ATP 
and ADP to adenosine. In detail, the conversion of ATP/
ADP to AMP is performed by ectonucleoside triphosphate 
diphosphohydrolase-1 (CD39), which is induced during 
hypoxic or ischemic conditions. Studies implicate the tran-
scription factor specificity protein 1 (Sp1) to be crucial in 
the induction of CD39 gene expression.22,33 The conversion 
of AMP to adenosine is catalyzed by ecto-5′-nucleotidase 
(CD73), which is a direct HIF target; CD73 expression is 
found elevated during hypoxia or ischemia in many organs 
and tissues.23 Similarly, the A2A and A2B adenosine receptors 
(A2AR and A2BR) are known HIF-target genes.34,35 As such, 
hypoxia signaling enhances the production and signaling 
effects of extracellular adenosine.
HIF activation represents a strong adaptive response 
to the change in oxygen levels. This response, when har-
nessed properly, can serve as a target to prevent periopera-
tive organ injury.32 Although HIF activation can be achieved 
via hypoxia and bacterial infection, those conditions should 
always be avoided in perioperative patients. Enhancing 
HIF by HIF activators can potentially serve as a preopera-
tive intervention to prevent organ injury. The mechanism by 
which HIF activators stabilize HIF is inhibition of PHDs.36,37 
Since PHDs use oxygen and 2-oxoglutarate (2-OG) as cosub-
strates, 2-OG analogues can act as competitive antagonists 
inhibiting the activity of PHDs.38,39 For instance, obstruc-
tive sleep apnea results in hypoxic conditions, which have 
been associated with insulin resistance and type 2 diabe-
tes.40 PHD inhibitors, such as AKB-4924 increase HIF-1α 
levels and enhance insulin secretion and glucose tolerance, 
implicating the possibility of HIF activators as a therapeutic 
approach for type 2 diabetes.41 Active clinical trials targeting 
hypoxia signaling are listed in the Table. In this review, we 
Figure 3. Control of extracellular adenosine generation and signaling during inflammation by hypoxia. During inflammatory conditions, multiple 
cell types release nucleotides, including activated inflammatory cells, apoptotic cells and necrotic cells, typically in the form of adenosine 
triphosphate (ATP) or adenosine diphosphate (ADP) from the intracellular compartment into the extracellular space. In acute organ injury, a 
decrease in oxygen supply (eg, due to vessel thrombosis) and significant increases in oxygen demand result in an imbalance in oxygen avail-
ability. Hypoxia causes Sp1-dependent induction of ectonucleoside triphosphate diphosphohydrolase 1 (CD39)22 and a hypoxia-inducible fac-
tor (HIF)–dependent induction of ecto-5′nucleotidase (CD73).23 Extracellular adenosine is generated primarily from the enzymatic conversion 
of ATP and ADP by CD39 and CD73. Extracellular adenosine can signal through 4 distinct adenosine receptors: adenosine A1 receptor (A1R), 
adenosine A2A receptor (A2AR), adenosine A2B receptor (A2BR), and adenosine A3 receptor (A3R). For example, activation of A2AR on inflam-
matory cells such as neutrophils24 or lymphocytes attenuates inflammation.25–27 As shown in other experimental studies, signaling events 
through A2BR facilitate tissue adaptation to hypoxia and attenuation of acute lung injury and ischemia/reperfusion injury.28,29 Activation of 
adenosine A2AR30 and A2BR31 dampens intestinal inflammation and promotes epithelial integrity during intestinal inflammation. Current study 
suggested that adenosine receptor agonist has therapeutic potential to prevent and treat perioperative organ injury. Adapted from Eltzschig 
et al .32 Copyright © 2012 Massachusetts Medical Society. AMP indicates adenosine monophosphate.
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summarize past, current, and emerging therapeutic strate-
gies targeting hypoxia signaling for 4 select conditions: MI, 
ARDS,  AKI, and AGI.
MYOCARDIAL INFARCTION
MI is clinically characterized by abnormally high levels of 
plasma cardiac troponin concentration accompanied with at 
least 1 of the following criteria: ischemia, electrocardiogram 
abnormality, detection of intracoronary thrombus, or wall 
motion abnormality.42 The incidence of MI ranges from 1% 
to 3% in major noncardiac surgery and according to a multi-
center international cohort study, MI results in about 5 times 
higher mortality rates (from 2.2% to 11.6%).43–45 Prolonged 
ischemia leads to the death of cardiomyocytes and causes 
MI, which is further categorized into type 1 and type 2 MI. 
Type 1 MI is usually caused by ischemia that results from 
acute coronary occlusion after the rupture of an atheroscle-
rotic plaque.46 On the other hand, type 2 MI is defined as 
ischemic imbalance from conditions unrelated to coronary 
artery diseases including anemia, arrhythmia, hypotension, 
and hypertension.42 Existing therapeutic interventions for 
MI include fibrinolytic therapy, β-blockers, antiplatelet/
anticoagulant agents, percutaneous coronary intervention 
(PCI), nitrates, and statins. For example, revascularization 
therapies, such as PCI with stents or balloon angioplasty or 
surgical revascularization by coronary artery bypass graft-
ing, are very frequently utilized. Additionally, prevention 
of subsequent thrombotic events with the use of antiplate-
let or anticoagulant medications is very common. Finally, 
supplemental oxygen therapy is frequently used as an initial 
treatment in patients experiencing MI, but its routine use 
has become somewhat controversial. Although the effective-
ness of traditional management of MI to reduce mortality 
has been proven, there are certain limitations.12 For instance, 
the accessibility of PCI-capable hospitals could be limited in 
rural areas while fibrinolytic therapy and antiplatelet/anti-
coagulant reagents could lead to potential detrimental side 
effects including stroke, which is commonly caused by brain 
hemorrhage. Most of the mentioned therapies for MI have 
the potential of introducing a new element of risk to patients, 
so it is essential to develop novel perioperative therapies to 
reduce the incidence of MI in a preventative manner and fur-
ther decrease postoperative death related to MI.
Hypoxia that occurs with MI leads to the stabilization of 
HIF,47 and several studies have suggested a cardioprotec-
tive role of HIF,28,48 which at least in part could be related to 
alterations in purinergic signaling events.49 Multiple stud-
ies have indicated the protective role of adenosine signaling 
in organ injury including the heart.50–54 The A2BR in par-
ticular has shown promising cardioprotective effects dur-
ing myocardial ischemia/reperfusion injury. For instance, 
adora2b deletion in mice abolishes the protective effect of 
ischemic preconditioning (IPC) marked by increased infarct 
size after ischemia/reperfusion.55 Moreover, A2BR confers 
its protective activity via stabilization of circadian rhythm 
protein Period 2 (Per2),28 which supports the concept of 
light therapy for cardioprotection.48 Interestingly, cardiac 
Per2 levels fluctuate during the day with the highest lev-
els of Per2 in the afternoon and early evening while lowest 
Per2 levels have been observed during the morning hours. 
Consistently, myocardial infarct size was largest during 
the morning hours while smallest in the evening, suggest-
ing an inverse correlation between Per2 levels and infarct 
size. Despite the hypothetical nature, cardiac stabilization 
of Per2, such as via light therapy, might be considered as a 
novel therapy to reduce infarct size and attenuate ischemic/
reperfusion injury in patients.
Several studies have been conducted to demonstrate the 
safety and effectiveness of targeting HIF/adenosine signal-
ing in the treatment of MI. Remote ischemic preconditioning 
(RIPC), which involves the repetitive ischemia/reperfusion 
to an arm or a leg before an ischemic condition in the myo-
cardium, has shown significant myocardial protection.56 
HIF-1α is essential for RIPC-induced myocardial protection 
Table. Example of Clinical Trials Targeting Hypoxia Signaling




Dialysis subjects with anemia 
associated with chronic kidney 
disease (phase III)
Study the safety and efficacy of  
daprodustat compared to erythropoietin, 
following a switch from erythropoietin- 
stimulating agents
NCT02879305 (recruiting)
Patients undergoing elective 
descending thoracic aorta/ 
thoracic aortic aneurysm (DTA/ 
TAAA) repair (phase II)
Test the hypothesis that GSK1278863 will 





Subjects with incident dialysis- 
dependent chronic kidney  
disease (phase III)
Evaluate the efficacy and safety of oral 
vadadustat for the correction of anemia
NCT02865850 (recruiting)
Roxadustat/ FG-4592 
(FibroGen, San Francisco, 
CA; Astellas Pharma, 
Northbrook, IL; AstraZeneca, 
Wilmington, DE)
Chronic kidney disease patients  
not on dialysis (phase III)
Study the efficacy and safety of FG-4592  




Patients with chronic systolic  
heart failure (phase II)
Investigate the safety, tolerability, 
pharmacokinetics, and acute 
cardiovascular responses of a 7-day oral 





Patients with acute respiratory 
distress syndrome (phase III)
Investigate the impact of liberal versus 
conservative oxygenation on mortality
NCT02713451 (recruiting)
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because gene silencing of HIF-1α was shown to abolish the 
protective effect of RIPC.57 Furthermore, a recent study by 
Sarkar et al58 demonstrated a very interesting effect of HIF 
inhibitor to diminish the protection from IPC. Interestingly, 
this study showed mice with knockout of HIF-1α or HIF-
1β in bone marrow  and vascular endothelial cells to have 
complete absence of protection induced by IPC, whereas 
adenosine infusion restored the protection by IPC in these 
mice. Several pharmacological compounds are available, 
both promoting the stabilization of HIF via inhibition of 
oxygen sensors, such as PHDs, and further inducing the 
modulation of HIF-dependent genes. Although PHD inhibi-
tors have not been tested in clinical trials for their effective-
ness in the attenuation of MI, their safety has been proven 
in several clinical trials targeting anemia in chronic kidney 
injury (Table). In animal models, pretreatment with dimeth-
yloxaloylglycine (DMOG), a 2-OG analogue, results in a sig-
nificant reduction in infarct size after ischemic/reperfusion 
injury, which is accompanied by a considerable reduction 
of interleukin-8 when compared with sham-treated mice.59 
Moreover, in vivo pretreatment with small interfering RNA 
silencing PHD2 attenuates murine myocardial infarct sizes, 
through modulation of A2BR signaling.60
Besides the pretreatment with HIF activators, eliciting 
the adenosine pathway can also serve as a novel thera-
peutic option to treat MI. For example, adenosine infusion 
has been proven to be effective during MI in clinical set-
tings.61 Higher concentrations of adenosine correlated with 
reduced myocardial infarct sizes and the administration of 
adenosine within the first 3 hours after MI onset increased 
patient survival.62,63 Notably, the clinical effect of adenosine 
infusion is limited due to its short half-life. Consequently, 
there is great potential for adenosine receptor agonists 
as novel therapies for MI. Indeed, mice treated with BAY 
60-6583, a specific agonist of A2BR, showed significant pro-
tection against MI marked by reduced infarct sizes in wild-
type mice but not in mice with adora2b deletion.29,55 Taken 
together, HIF activators, A2BR agonists, as well as light 
therapy represent potential therapeutic approaches in the 
attenuation of MI in patients.
ACUTE RESPIRATORY DISTRESS SYNDROME
ARDS is an inflammatory disorder of the lung creating sig-
nificant impairment of oxygen exchange. It is defined by 
its clinical characteristics, including the following: (1) acute 
onset after pulmonary insult or manifestation, (2) radio-
logic imaging showing unexplained bilateral alveolar opaci-
ties, and (3) exclusion of heart failure or fluid overload as a 
cause of respiratory failure.64 The term “acute lung injury” 
has somewhat fallen out of favor in the description of this 
range of inflammatory lung pathology due to the variability 
in its practical use. The newly published Berlin definition of 
ARDS proposed subcategories based on the degree of hypox-
emia (that would have previously encompassed the entity of 
“acute lung injury”): mild (Pao2/Fio2 ≤300 mm Hg), mod-
erate (Pao2/Fio2 ≤200 mm Hg), and severe (Pao2/Fio2 ≤100 
mm Hg).64 The incidence of ARDS was reported to be 0.2% 
in patients undergoing general surgery and increased to 3% 
to 26% in patients with different risk factors such as higher 
risk surgeries, infection, and smoke inhalation.65,66 Contrary 
to the relative low incidence of ARDS in general surgery, the 
mortality of ARDS is high compared with other periopera-
tive organ injuries, ranging from 27% to 40%.66,67 Both direct 
pulmonary injuries, such as pneumonia, aspiration, or pul-
monary contusion, and indirect insults, such as sepsis, blood 
transfusion, shock, or pancreatitis, can result in ARDS.53,68–72 
Premorbid conditions may be predictive of which patients 
may develop perioperative ARDS, with possible implicat-
ing factors such as emergency surgery, advanced age, pre-
existing renal failure, preexisting chronic or infective lung 
disease, and alcohol abuse.73 Typical symptoms of ARDS 
include severe pulmonary edema and uncontrolled lung 
inflammation, which results in impaired oxygen uptake and 
the need for ventilation. Treatment for ARDS is supportive in 
nature and can range from supplemental oxygen administra-
tion to mechanical ventilation, which on its own represents 
a potential cause of ALI leading to further lung damage.74 
Management of mechanical ventilation in the setting of 
ARDS has been well described and is beyond the scope of 
this review; such strategies generally involve the use of low-
tidal volume ventilation and close management of pressure 
parameters seen in ventilation of an injured lung.75 The same 
protective lung ventilation may be helpful in preventing 
ARDS as well, but there is continued debate on the effective-
ness of such strategies.73 In extreme circumstances, extra-
corporeal membrane oxygenation may be utilized to allow 
for adequate oxygen delivery to the body and essentially 
allowing the lungs to rest for recovery. Several therapeutic 
reagents, such as methylprednisolone and omega-3 fatty 
acids, have been tested in clinical trials but proven ineffective 
in improving outcomes,76,77 which drives the search for novel 
therapeutic targets to reduce ARDS mortality.
Several factors contribute to the stabilization of pulmo-
nary HIF during ALI. Besides “inflammatory hypoxia” and 
infection, which are explained in the introduction, other 
studies show that mechanical ventilation and concomitant 
cyclic mechanical stress can lead to the repression of the 
activity of succinate dehydrogenase. Subsequent eleva-
tions of pulmonary succinate levels during alveolar epithe-
lial stretch can lead to inhibition of PHDs, as succinate is 
a known PHD inhibitor.7 Taken together, several pathways 
are likely to converge during conditions of ARDS result-
ing in the stabilization of HIFs. It may seem counterintui-
tive that an organ that is as highly oxygenated as the lungs 
can functionally experience hypoxia signaling. However, 
inflammatory and metabolic changes during ARDS account 
for the stabilization of HIFs, and HIF-dependent altera-
tions in gene expression have been shown to dampen lung 
inflammation. Metabolic lung protection by HIFs includes 
the optimization of carbohydrate metabolism in pulmonary 
epithelial cells.7 In an in vivo murine model of ALI, HIF-1α 
stabilization was observed under normoxic condition dur-
ing ventilation-induced lung injury. Alterations in alveolar 
epithelial metabolism induced an HIF-dependent increase 
in glycolytic flux rates that provided a metabolic advantage 
in wild-type as opposed to mice with induced deletion of 
alveolar epithelial HIF-1α.7 Moreover, alveolar epithelial-
specific HIF-1α deletion resulted in significant reduction in 
survival in a murine model of ALI.7 The same study also 
showed the HIF activator, DMOG as being beneficial while 
the HIF inhibitor, echinomycin resulted in a detrimental out-
come of ALI. Together, these findings suggest that alveolar 
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epithelial HIF stabilization functions to optimize carbohy-
drate metabolism during ARDS, and thereby dampens lung 
inflammation. Extensions of these findings indicate the pos-
sibility that inhaled HIF activators could in the future be 
used for ARDS treatment.
Other studies implicate alterations in purinergic signal-
ing in mediating HIF-dependent lung protection. HIF signal-
ing shifts the balance between proinflammatory ATP/ADP 
signaling to anti-inflammatory adenosine signaling via the 
induction of CD39 and CD73.78,79 Similarly, HIF-mediated 
increases in adenosine signaling, particularly through the 
A2BR, have been linked to improved alveolar fluid trans-
port and attenuated lung inflammation.80,81 Interestingly, 
HIF-1α-dependent induction of netrin-1 was observed in 
hypoxia-induced inflammation and netrin-1-dampened 
neutrophil transepithelial migration by engaging A2BR in 
both hypoxia-induced inflammation and LPS-induced lung 
injury.82,83 Additionally, A2BR was induced in both in vitro 
stretch studies and an in vivo ventilation-induced lung injury 
model while its induction was abolished after HIF inhibition 
or genetic deletion of HIF-1α.34 Furthermore, aerosolized 
BAY 60-6583, an A2BR agonist, has been shown to attenu-
ate pulmonary pathophysiology after ALI and trauma-
hemorrhagic shock-induced lung injury.84,85 Collectively, 
HIF activators and adenosine receptor agonists appear to be 
promising therapeutic targets in the treatment of ARDS.
OXYGENATION IN THE PERIOPERATIVE SETTING
Hypoxia signaling, particularly stabilization of HIF pro-
tein or the induction of HIF target genes, have been impli-
cated in the protection against acute organ injury, such as 
MI, ARDS, AKI, and AGI. A concern in this context has 
been that potentially higher levels of oxygen concentration 
(hyperoxia) could prevent the activation of these tissue-pro-
tective and anti-inflammatory pathways under the control 
of HIFs. Clinicians may have to exercise a careful balance 
as profound hypoxia in perioperative patients could lead to 
brain injury or detrimental injuries in other organ systems. 
Therefore, utilization of higher oxygen concentrations may 
frequently be imperative in order to avoid hypoxic injury to 
these organs (“Yin and Yang”; see Figure 4). For example, 
reviewing the clinical literature fails to elucidate an “ideal” 
concentration for oxygen delivery in the prevention and 
treatment of ARDS. Some reviews suggest a Pao2-driven 
model for supplemental oxygen delivery and indicate that 
Pao2 >100 mm Hg may create “hyperoxia” conditions, with 
potential problems including atelectasis, systemic vascular 
constriction, proinflammatory states, and tissue damage 
caused by reactive oxygen species.86 Based on these find-
ings, there has been a recent interest in perioperative studies 
to clinically define proper concentrations of oxygen.
Basic science studies have demonstrated the potential det-
rimental effect of hyperoxia on acute organ injury. For exam-
ple, a landmark study from the laboratory of Dr Sitkovski 
demonstrated that “hyperoxygenation” could have a detri-
mental role in the development and exacerbation of ALI.87 In 
this study, mice receiving 100% oxygen showed significantly 
reduced survival rates in a bacterial infection-induced ALI 
model, when compared with mice receiving lower levels of 
oxygen. Mechanistically, this study suggested that higher 
levels of oxygen dampen the anti-inflammatory effects of 
HIFs and its concomitant role in promoting adenosine sig-
naling and could therefore be detrimental. These findings 
would advise against the excessive use of high oxygen con-
centration in clinical settings as a supporting treatment of 
ARDS because superoxygenation might lead to increased 
mortality due to attenuated HIF responses.
The feasibility and safety of conservative oxygenation dur-
ing the intraoperative phase have been investigated by several 
clinical studies. For instance, a randomized controlled trial 
conducted by Smit et al88 evaluated the effect of near-physio-
logical oxygen targets on myocardial damage, organ function, 
and oxidative stress compared to standard care during and 
after coronary artery bypass surgery. In this study, a total of 
50 patients were enrolled and randomized to receive conven-
tional oxygenation (Pao2 target of 200–220 mm Hg during car-
diopulmonary bypass and 130–150 mm Hg during intensive 
care unit [ICU] admission) or near-physiological oxygenation 
(Pao2 target of 130–150 mm Hg during cardiopulmonary 
bypass and 80–100 mm Hg during ICU). The study concluded 
that conservative oxygen administration was not associated 
Figure 4. The “Yin and Yang” of oxygenation in the perioperative 
setting. In the clinical setting, utilizing high oxygen concentrations 
(“Hyperoxia”) during the perioperative period or in critical care patients 
may be associated with an increased “safety margin” to avoid peri-
operative hypoxia and hypoxia-driven organ injury. However, hyperoxia 
has been implicated in promoting tissue injury by elevating levels of 
reactive oxygen species, and some clinical studies suggest worse 
outcomes associated with such approaches. At the same time, utiliz-
ing high inspired oxygen concentrations has the potential to dampen 
tissue-protective and anti-inflammatory pathways under the control 
of hypoxia-inducible transcription factors (HIFs), such as extracellular 
adenosine signaling. There appears to be a “Yin and Yang” with a 
U-shaped relationship between hyperoxia and conservative oxygen 
therapy. It will be critical for the perioperative field to find the “optimal 
oxygen concentration” for individual clinical scenarios. Different clini-
cal studies have indicated that conservative oxygen therapy can be 
utilized safely in surgical or critical care patients, without increasing 
the risk of organ injury or wound infections. While we are awaiting the 
results of larger scale trials, the current evidence indicates oxygen 
conservative therapy as safe and associated with better outcomes—
at least in some of the measurements. In the context of the current 
review, some of the improved outcomes with conservative oxygen 
therapy could potentially be mediated by a more robust activation of 
the “HIF” pathway and concomitant organ protection.
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with increased lactate levels or hypoxic events during surgery 
and ICU stay, supporting the safety and feasibility for conser-
vative intraoperative oxygenation. Additionally, the PROXI 
randomized clinical trial (NCT00364741) suggested that 
when compared with conservative perioperative oxygen frac-
tion (30%), high perioperative oxygen fraction (80%) offers no 
benefit on surgical outcome, as marked by the incidence of 
surgical site infection and secondary pulmonary complica-
tions.89 All things considered, conservative oxygenation dur-
ing surgery seems to be safe and feasible, and further study is 
needed to identify the impact of conservative oxygenation on 
perioperative outcomes.
The feasibility and safety of conservative oxygenation 
in the ICU has also been supported by several clinical stud-
ies.90,91 Furthermore, the beneficial effect of conservative oxy-
genation in the ICU was shown by a recent clinical trial by 
Girardis et al.92 In this trial, a total of 434 patients with a min-
imum duration of 72 hours in ICU randomly received either 
conventional (target peripheral capillary oxygen saturaton 
[Spo2] 97%–100%) or conservative (target Spo2 94%–98%) 
oxygen therapy. For both, in the context of ICU mortality and 
the occurrence of new organ failure and infection, patients in 
the conservative study arm showed better results. Results 
from all these pilot studies mentioned above justified the 
conduction of larger randomized controlled trials. Indeed, 
a phase III clinical trial (NCT02713451) is currently recruit-
ing to test whether restrictive oxygenation could lower the 
28-day mortality of ARDS patients in the ICU when com-
pared with liberal oxygenation therapy. In summary, conser-
vative oxygenation seems to be safe and feasible during ICU 
stays with further study ongoing to support the beneficial 
effect on patient outcomes.
The use of oxygen in the management of patients expe-
riencing MI has been under debate for decades. Once 
considered the standard treatment for patients experienc-
ing MI, the beneficial effect of oxygen supplementation to 
improve myocardial oxygenation and reduce infarct size 
has not been proven by evidence-based studies.93 It is unar-
guable that in certain patients with profound hypoxemia, 
oxygen supplementation would be crucial to maintain 
physiological oxygen levels. However, excess use of oxy-
gen could potentially be detrimental in MI patients without 
hypoxemia because hyperoxia might raise blood pressure, 
lower myocardial oxygen delivery, and capillary density.94 
A meta-analysis by Cabello et al95 summarized 3 trials 
involving 387 patients and suggested the lack of evidence 
to support oxygen supplementation in the improvement 
of patient mortality. In addition, the air verses oxygen in 
myocardial infarction study (AVOID) clinical trial investi-
gators (NCT01272713) analyzed the clinical outcomes of 441 
patients with ST segment elevation MI receiving air or oxy-
gen supplementation.96 Indeed, patients with supplemental 
oxygen displayed increases in peak creatine kinase level, 
incidence of recurrent MI, and frequency of cardiac arrhyth-
mia. Large-scale clinical trials would be essential to evaluate 
the proper oxygen supplementation in the management of 
MI patients, while currently the clinical guideline has been 
evolving and suggested oxygen supplementation only in 
patients with hypoxemia.
In summary, the safety and efficiency of conservative 
oxygen therapy in surgical and critical care patients have 
been established by clinical studies and in the meantime 
implying that hyperoxia might be “too much of a good 
thing” under certain circumstances. For instance, intra-
operative oxidative stress was implicated as a predic-
tor for the development of AKI in patients with cardiac 
surgery.97 Moreover, the association between hyperoxia 
(Pao2 ≥300 mm Hg) and increased in-hospital mortality 
has been established by Kilgannon et al98 in patients after 
resuscitation from cardiac arrest. A recent systemic review 
and meta-analysis by Damiani et al summarized total of 6 
clinical studies in patients postcardiac arrest and demon-
strated an association between hyperoxia and increased 
mortality, despite the heterogeneity of the included stud-
ies. In the context of the current review, it is important to 
point out that hyperoxia may potentially dampen endog-
enous tissue-protective responses that are under the con-
trol of HIFs. While we are awaiting the results of larger 
scale trials, the current evidence points toward a more 
conservative oxygen therapy as safe and associated with 
better outcomes—at least in some of the measurements. 
In conclusion, it will be critical for the perioperative field 
to find the “optimal oxygen concentration” for individual 
clinical scenarios to improve surgical outcomes and to 
prevent perioperative organ injury.
ACUTE KIDNEY INJURY
AKI is clinically characterized by decreased urine output, 
increased serum creatinine levels, and decreased glomer-
ular filtration rates. Kidney ischemia caused by reduc-
tion of renal blood flow that results in AKI can especially 
occur after surgical procedures.100 In addition, infection, 
anemia, and low cardiac output can also cause AKI. The 
incidence of AKI is estimated to be only 1% in patients 
receiving general surgical procedures, but strikingly the 
mortality rate of perioperative AKI is at 42%, according to 
a recent cohort analysis of 75 952 patients.101 The primary 
goal in approaching perioperative AKI is to prevent fur-
ther insult by mitigating possible causes of AKI and pre-
venting further renal damage from nephrotoxic drugs.102 
To date, most therapeutic approaches to prevent or treat 
AKI have been deemed unsuccessful or even harmful, as 
the majority of interventional clinical trials in AKI have 
failed.103,104 The most recent Cochrane analysis regarding 
perioperative AKI found a significant amount of heteroge-
neity in patients’ responses and failed AKI protection in a 
number of studied interventions, including dopamine and 
dopamine analogues, diuretics, calcium channel blockers, 
angiotensin-converting enzyme inhibitor drugs, N-acetyl 
cysteine, sodium bicarbonate, antioxidants, erythropoi-
etin, and IV fluid administration.105 Importantly, a mul-
ticenter, randomized RenalRIP trial demonstrated that 
RIPC leads to both short-term and long-term postopera-
tive kidney protection in patients undergoing high-risk 
cardiac surgery,106,107 although large-scale multicenter tri-
als are crucial to optimize the RIPC protocol for efficient 
renal protection.108
The adaptive response to hypoxia leads to the stabiliza-
tion of HIF via inhibition of PHDs, which is also observed 
in renal hypoxia and ischemia-/reperfusion-induced AKI. 
Several studies have demonstrated HIF stabilization and 
induction of HIF-dependent genes in renal protection 
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during AKI.109 For instance, human renal tubular cells 
obtained from renal transplants were found to express 
increased levels of HIF-1α, which were positively correlated 
with better clinical outcome.110 Similarly, HIF accumulation 
was observed in wild-type mice exposed to no-flow isch-
emia-induced AKI, as well as in ischemic rat kidneys.36,111 
To further illustrate the importance of HIF in the protec-
tion of AKI, studies have shown that the severity of isch-
emia/reperfusion injury in AKI is significantly increased 
in heterozygous HIF-1α-deficient mice.36 Additionally, a 
recent study demonstrated that endothelial-specific HIF-2α 
expression exhibits a protective role in murine models of 
ischemia-/reperfusion-induced AKI.112 In search for HIF-
targeting genes in renal cells, Yang and Zou113 identified 
heme oxygenase-1 (HO-1) as an HIF-1α gene target in renal 
medullary interstitial cells. The same group also demon-
strated that induction of HO-1 significantly reduced oxi-
dative stress-induced cell injury in human renal proximal 
tubular epithelial cells and that HO inhibitor, Tin protopor-
phyrin (SnPP), reversed this protection.114
Several preclinical studies have successfully demon-
strated the effectiveness of HIF activators in the protection 
against ischemia-/reperfusion-induced AKI, suggesting the 
potential of utilizing pharmacological activation of HIF as 
therapeutic treatment. For example, HIF activator DMOG 
exhibited strong renal protection in a murine model of isch-
emic AKI.36 Ahn et al37 have also showed a similar result, 
demonstrating a renal protecting effect of DMOG in gen-
tamicin-induced AKI. Indeed, DMOG treatment in vivo 
attenuated gentamicin-induced AKI by reducing renal dys-
function, proteinuria, and kidney pathology. Another study 
described that only pretreatment with DMOG confers renal 
protection while treatment during the early recovery phase 
of AKI does not confer renal protection, strongly suggest-
ing the potential of HIF activators as preventative strate-
gies.115 Treatment using a novel HIF hydroxylase inhibitor, 
TRC160334, also mediated protection against ischemic AKI 
in a rat model of ischemia-/reperfusion-induced AKI.116 
Additionally, acetazolamide, commonly prescribed to treat 
glaucoma and high-altitude mountain sickness, is known to 
be a potent inducer of HIF-1α.117 Treatment with acetazol-
amide provided renal protection in a murine model of AKI, 
resulting in decreased creatinine and blood urea nitrogen 
levels.117 Furthermore, several clinical trials have tested the 
effect of HIF stabilization and/or PHD inhibition as treat-
ment for anemic patients with renal injury. Taken together, it 
will be of great interest to test the safety and potential effec-
tiveness of HIF activators in the prevention and treatment of 
AKI in clinical settings. Particularly, during surgical proce-
dures with a high incidence of AKI, such as thoracoabdomi-
nal aortic aneurysm repair, HIF activators may potentially 
contribute significantly toward improving patient outcomes 
by preventing ischemia/reperfusion injury of the kidneys.
ACUTE GUT INJURY
The intestine plays a central role in promoting the transition 
from single organ injury to multiorgan failure in periopera-
tive patients, and prevention of AGI is among the corner-
stones in preventing multiorgan failure and sepsis.69,118,119 
For example, experimental studies indicated that ischemic 
injury to the liver or the kidney will subsequently trigger 
intestinal dysfunction and a dramatic decrease in barrier 
function.120 Indeed, in vivo studies of acute kidney or liver 
ischemia revealed that distant organ ischemia could affect 
the physiologic functions of the intestine.120,121 This disturbed 
intestinal homeostasis affects the intestinal barrier function 
with mucosal disintegration, release of inflammatory medi-
ators from Paneth cells, induction of mucosal inflammation, 
and translocation of intestinal microorganisms. Therefore, 
AGI-induced intestinal inflammation can facilitate sys-
temic inflammation and, in patients at risk, favors the onset 
of sepsis and leads to multiple organ failures. It has been 
postulated that bacterial translocation from the intestinal 
lumen and release of mucosal microbiome contents are at 
least partially responsible.122,123 Extensive AGI can also be 
caused by mesenteric ischemia as a result of low-flow states, 
especially in surgeries utilizing aortic occlusion, cardiopul-
monary bypass, or circulatory arrest, and potentially leads 
to significant hypoxia in the intestinal mucosa. The inci-
dence of AGI ranges from 0.3% to 6.1% in patients undergo-
ing cardiopulmonary bypass or lung transplant surgeries, 
and the frequency of mesenteric ischemia is estimated to be 
0.15%.124 Given the emergency nature of extensive AGI and 
its associated systemic inflammatory responses, the mortal-
ity of AGI is high, ranging from 18% to 58%.124,125
AGI is regularly accompanied by gastrointestinal (GI) 
inflammation, which can be associated with profound 
hypoxia, leading to HIF stabilization via post-translational 
modification by PHDs and to the release of adenosine 
into the lumen of the GI tract. Under pathological condi-
tions, both HIF-1α and HIF-2α activation were observed in 
patients with intestinal inflammation, as well as in mice in 
experimental models of colitis.126–129 Interestingly, the func-
tion of HIFs, especially HIF-1α, was shown to be beneficial 
to improve disease outcome during gut inflammation.6,130 
For instance, tissue-specific deletions of HIF-1α in intestinal 
epithelial cells resulted in increased intestinal inflamma-
tion and more severe disease during murine models of coli-
tis.4,6,126,131,132 Particularly, HIF-1α deletion was associated 
with profound weight loss, enhanced intestinal inflamma-
tion, and colonic shortening, all signs of exaggerated AGI 
and dysfunction.126 Consistently, deletion of VHL or PHD1, 
which results in increased HIF stabilization, was shown to 
be protective during intestinal inflammation.126,133 Moreover, 
mice with PHD1 deletion showed reduced susceptibility to 
the development of colitis as characterized by attenuated 
weight loss, lower levels of disease activity, improved colon 
histology, reduced neutrophil infiltration, and decreased 
cytokine expression.133 Collectively, HIF activation is essen-
tial in the control of GI inflammation.
Hypoxia-induced HIF stabilization leads to the activation 
of multiple target genes that are responsible for the protective 
function of HIF during intestinal inflammation. For example, 
in the absence of CD39, mice developed increased severity 
of experimental colitis.134 Similarly, genetic deletion of CD73 
or administration of CD73 inhibitor α, β-methylene ADP 
resulted in increased severity of trinitrobenzene sulfonate-
induced murine colitis marked by increased weight loss and 
colonic shortening.135 Moreover, the protective role of CD73 in 
sepsis was supported by the observation of increased mortal-
ity in CD73-deficient mice after cecal ligation and puncture.136 
Similar findings in models of intestinal ischemia/reperfusion 
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injury highlighted functional roles of the CD39/CD73 path-
way and signaling events through adenosine receptors in gut 
protection.51,131,137 HIF and its target gene CD73 also function 
through promoting regulatory T (Treg) cells during murine 
model of intestinal inflammation.138,139 Treg cells are a group 
of CD4+ T cells that dampen inflammation through inactiva-
tion of effector T cells. Additional studies identified forkhead 
box P3 (FOXP3) as a HIF-1α target gene, suggesting the role 
of HIF-1α in Treg cell functions in mitigating mucosal inflam-
mation.138,140,141 For instance, deletion of HIF-1α in Treg cells 
attenuated their capability to suppress gut inflammation in a 
T cell transfer model of intestinal inflammation.138 Similarly, 
and as seen in various acute organ injury models, adenos-
ine signaling has anti-inflammatory effects through activat-
ing adenosine receptors, including A2AR and A2BR in GI 
inflammation.30 For instance, the transfer of A2AR-deficient 
CD45RB(low) CD25+ T cells failed to block colitis induced by 
pathogenic CD45RB(high) T cells, and treatment with an A2AR 
agonist inhibited proinflammatory cytokine production. 
Additionally, the severity of dextran sodium sulfate-induced 
colitis was increased in A2BR-deficient mice compared to 
wild-type counterparts, suggesting the potential of adenosine 
receptor agonists as treatments for intestinal inflammation.142
Several studies have demonstrated that pharmacological 
compounds increasing HIF stabilization are beneficial dur-
ing intestinal inflammation. For instance, mice treated with 
HIF activator DMOG showed profound improvements of 
multiple disease parameters, including weight loss, intes-
tinal inflammation, and histologically observed tissue 
injury during chemically induced colitis.127 The beneficial 
effect of another PHD inhibitor, TRC160334, has also been 
demonstrated in both  trinitrobenzene sulfonate-induced 
and  dextran sodium sulfate-induced murine models of 
intestinal inflammation. TRC160334 treatment attenuated 
weight loss, reduced the overall disease activity index, and 
improved macroscopic and microscopic scores of colonic 
damage.143 Similarly, another PHD inhibitor, AKB-4924, 
has been shown to have significantly protective effects in 
murine models of intestinal inflammation144 or models 
of intestinal ischemia/reperfusion injury.131 In addition, 
a protective effect of A2BR agonist, BAY 60-6583 in acute 
intestinal inflammation has been demonstrated in experi-
mental studies as well.145 Indeed, in murine models of acute 
intestinal inflammation, treatment with the specific A2BR 
adenosine receptor agonist BAY 60-6583 mediated mucosal 
protection characterized by attenuated colonic shortening, 
reduced tissue cytokines, and improved histological scores. 
Notably, the safety of oral PHD inhibitors, AKB-6548 and 
FG-4592, has been strongly supported by several clinical tri-
als for renal diseases (Table). Thus, the potential use of oral 
delivery of HIF stabilizers could represent a safe and novel 
therapeutic approach for AGI. As such, this local adminis-
tration approach may limit potential side effects from sys-
temic administration of HIF activators.
PHARMACOLOGIC HIF ACTIVATORS
HIF activation can be achieved by inhibition of PHDs, which 
leads to HIF stabilization under normoxic conditions. There 
are several classes of compounds to inhibit the function of 
PHDs by preventing the binding of cosubstrate 2-OG, includ-
ing iron chelators, CUL2 deneddylators and 2-OG mimics.4 
For instance, DMOG mimics the structure of 2-OG and has 
been shown to inhibit the function of PHDs in several animal 
models, as mentioned in previous paragraphs. Oral appli-
cation of these 3 HIF activators is currently being trialed in 
the clinical settings: vadadustat (AKB-6548, sponsored by 
Akebia, Cambridge, MA), roxadustat (FG-4592, sponsored 
by FibroGen, San Francisco, CA; Astellas, Northbrook, IL; 
and AstraZeneca, Wilmington, DE), and daprodustat (GSK-
1278863, sponsored by GlaxoSmithKline, Philadelphia, PA). 
The length of clinical trials of PHD inhibitors varies from 4 
to 52 weeks. Once-daily oral administration of vadadustat 
has been shown to be effective in maintaining and increasing 
hemoglobin level after 2 weeks of treatment, as represented 
in a phase-2b study to test vadadustat as anemia treat-
ment in nondialysis-dependent chronic kidney disease.146 
Additionally, a phase-2 clinical study by Besarab et al147 
implicated that the time to respond to biweekly oral appli-
cation of roxadustat ranges from 14 to 21 days in patients 
treated with higher dose of roxadustat (2 mg/kg), as marked 
by increases in hemoglobin levels. Collectively, oral avail-
able PHD inhibitors have been assessed in clinical settings to 
be effective as treatment of anemia in chronic kidney disease 
patients, and it is reasonable to pursue PHD inhibitors as a 
novel therapeutic approach for perioperative organ injury.
Given the diverse functions of HIF in a multitude of devel-
opmental, physiological, and pathophysiological processes, 
altering such a pathway has its own limitations, especially 
in chronic setting. Several concerns of HIF activators have 
been raised from basic research and preclinical studies. For 
example, Xue et al148 demonstrated that HIF-2α activation via 
disruption of VHL promoted colorectal cancer progression in 
mice. Additional study in murine model of tubulointerstitial 
fibrosis indicated that HIF activation might have a detrimen-
tal impact on the development of fibrosis.149 Fortunately, the 
safety of PHD inhibitors in patients has been established by 
several phase-2 clinical studies.146,147,150,151 However, 1 of the 
first-generation PHD inhibitor, FG-2216, was related to the 
development of fatal hepatic necrosis in 1 patient. Due to the 
single death event and abnormal liver enzyme test results 
from other patients, the phase-2 clinical trial of FG-2216 
has to be suspended. Since the discontinuation of studies 
in FG-2216, FibroGen developed a second-generation PHD 
inhibitor—roxadustat, and no significant hepatic adverse 
effect was observed in a phase-2b clinical study in patients 
with chronic kidney disease, suggesting that the case of 
hepatic necrosis related to FG-2216 might be an off-target 
effect. Another concern of the application of PHD inhibitor 
in the clinical settings involves the impact of HIF activation 
on erythropoiesis. Although increased erythropoietin expres-
sion is desirable for treatment of conditions such as renal 
anemia, increased risk of thromboembolic events can serve 
as an undesirable adverse effect. However, it is quite reassur-
ing that recent trials of vadadustat and roxadustat showed 
no increase in the incidence of hypertension and cardiovas-
cular events.146,150 In addition, HIFs can stimulate vascular 
endothelial growth factor (VEGF) release accompanied by 
increased vascular leakage; however, the concern of HIF acti-
vator-related VEGF release was alleviated by an encouraging 
phase-2 study to test the efficacy of daprodustat on anemia 
management.151 Indeed, there is no change observed in the 
level of circulating VEGF in the daprodustat treatment group 
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compared with placebo control. Meanwhile, the number of 
clinical trials for HIF activators as therapeutic interventions 
for perioperative organ injury has been thus far limited when 
compared with clinical trials in renal anemia. We believe that 
the primary reason for the lack of clinical trials could be that 
the tissue-protective effects of HIF activation in acute organ 
injury have only been recently discovered. Indeed, the rela-
tionship between HIF and erythropoietin and the important 
protective effects of this association was established decades 
ago. Further research in the protective effect of HIF activa-
tion in acute organ injury will facilitate our understanding 
of the mechanisms of action, which will avoid or minimize 
potential side effects from the treatment with HIF activators 
in perioperative settings. Taken together, the safety of HIF 
activation by PHD inhibitors is reassured by several clinical 
studies, and short-term use of HIF activators in perioperative 
medicine appears safe based on the safety records using HIF 
activators over extended time periods.
CONCLUSIONS
Perioperative organ injury is considered 1 of the leading 
causes of perioperative morbidity and mortality, and there 
is urgent need for the development of novel therapies for 
organ protection in surgical patients. Hypoxia signaling 
serves a protective role in multiple types of perioperative 
organ injuries, including MI,  ARDS, AKI, and AGI. It is 
important to note that these responses and the ultimate 
stabilization of HIF are considered adaptive to physiologic 
insult and that attempting to modulate them clinically by 
inducing hypoxia or inflammation would be inadvisable. 
However, targeting hypoxia signaling via HIF activators (in 
the absence of the physiologic insult) appears to be promis-
ing with a good safety profile of existing oral agents and the 
emergence of newer compounds on the horizon. In addi-
tion to potential benefits in perioperative organ injury, there 
may be additional advantageous effects of these agents. HIF 
activators also drive the expression of erythropoietin and 
increase red blood cell counts, a condition surgical patients 
could profit from by reducing their need for blood prod-
ucts and preventing transfusion-associated complications 
as well. Given the elective nature of most surgeries, HIF 
activators can possibly be administered preoperatively to 
induce the full potential of the beneficial effects. Besides 
HIF activation by PHD inhibitors, pharmacologic enhanc-
ers of HIF target genes can also be used to prevent periop-
erative organ injury. For instance, A2BR receptor agonists 
and small interfering RNA for PHDs or HIF target genes 
could represent novel therapeutic targets for periopera-
tive organ injury. However, the study of novel therapeutic 
approaches targeting hypoxia signaling is still in its infancy 
because of the lack of clinical studies focusing on this area. 
From this clinical perspective, it will be crucial to promote 
these novel therapeutic approaches by performing addi-
tional clinical trials and by increasing our understanding 
of the mechanisms of action, thereby eliminating possible 
safety concerns that hinder the progress from bench to bed-
side. Additionally, further knowledge identifying patient 
populations at higher risk for specific type of periopera-
tive organ injuries will allow for more targeted therapeutic 
approaches, ultimately allowing for a cost-effective and per-
sonalized approach to perioperative organ protection. E
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